Figure 4
Figure 4. IL-15 mediates the expansion of antigen-specific CD8+ but not CD4+ T cells. (A) Percent Ki-67+ SIV-specific (Gag and Nef averaged) and CMV-specific CD4+ T-cells and (B) CD8+ T cells before and after therapy introduction. N/A indicates data not available because of low number of responding cells. Data are expressed as in Figure 2B. #P < .05 vs ART; Wilcoxon rank-sum test. (C) Percent of Gag-, Env-, or CMV-specific CD4+ (top) and CD8+ (bottom) T cells producing cytokines (IL-2 or TNF-α or IFN-γ) in the different treatment groups in the peripheral blood at d−7 or at d46 after therapy initiation. Data are expressed as in Figure 1B. (D) As in panel C but in the ILN and the BAL at baseline (“pre”) and at d28. Data from the jejunum are not depicted because very low responses were detected.

IL-15 mediates the expansion of antigen-specific CD8+ but not CD4+ T cells. (A) Percent Ki-67+ SIV-specific (Gag and Nef averaged) and CMV-specific CD4+ T-cells and (B) CD8+ T cells before and after therapy introduction. N/A indicates data not available because of low number of responding cells. Data are expressed as in Figure 2B. #P < .05 vs ART; Wilcoxon rank-sum test. (C) Percent of Gag-, Env-, or CMV-specific CD4+ (top) and CD8+ (bottom) T cells producing cytokines (IL-2 or TNF-α or IFN-γ) in the different treatment groups in the peripheral blood at d−7 or at d46 after therapy initiation. Data are expressed as in Figure 1B. (D) As in panel C but in the ILN and the BAL at baseline (“pre”) and at d28. Data from the jejunum are not depicted because very low responses were detected.

Close Modal

or Create an Account

Close Modal
Close Modal